X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to evaluate invIOs’ small molecule INV501 that can selectively enhance anti-tumor immune responses, as a potential treatment for glioblastoma.
Lead Product(s): INV501
Therapeutic Area: Oncology Product Name: INV501
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dana-Farber Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 09, 2023
Details:
The funding will be used for a Phase 1b trial of its novel autologous cell therapy, APN401, an innovative approach that leverages invIOs’s proprietary EPiC cell therapy platform, in patients with solid tumors.
Lead Product(s): APN401
Therapeutic Area: Oncology Product Name: APN401
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Austrian Research Promotion Agency
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding September 06, 2023
Details:
INV501 is a novel oral small molecule candidate that can selectively enhance anti-tumor immune responses. It induces T cell activation, proliferation, and tumor-reactive cytotoxicity.
Lead Product(s): INV501
Therapeutic Area: Oncology Product Name: INV501
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2023
Details:
APN401 (siRNA-transfected peripheral blood mononuclear cells) is an Autologous Cell Therapy using siRNA mediated silencing of Cbl-b resulting in highly activated tumor-reactive white blood cells.
Lead Product(s): siRNA-transfected Peripheral Blood Mononuclear Cells
Therapeutic Area: Oncology Product Name: APN401
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2022
Details:
The first clinically validated target is the immune master-checkpoint Cbl-b; the clinical-stage lead candidate APN401 will show results in the near term on safety with data from an ongoing Phase 1b trial.
Lead Product(s): APN401
Therapeutic Area: Oncology Product Name: APN401
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
